DIAGNOSIS AND STAGING OF LUNG CANCER

https://doi.org/10.1016/S0272-5231(05)70010-1Get rights and content

The impact of lung cancer on the industrialized world is immense. Undeniably, the greatest risk factor is smoking and, because of increased numbers of women who smoke, lung cancer incidence has been on the rise in recent years. Lung cancer is now the leading cause of cancer death in both men and women in the United States.

This article discusses bronchogenic carcinoma with regard to the various modalities by which it can be diagnosed and the most appropriate clinical settings in which these modalities should be used. It also summarizes the most recent system for staging lung cancer, as well as discussing some adjunctive modalities for use in both diagnosis and staging. Neither treatment of lung cancer nor malignancy of the chest other than bronchogenic carcinoma is discussed here because they are beyond the intended scope of this article.

Section snippets

Screening

Although there are numerous recommendations from various organizations for screening and early detection of cancers such as breast, colorectal, and prostate, there are no such recommendations for lung cancer. Indeed, no organization recommends lung cancer screening of any sort at any time for asymptomatic patients. To date, there have been no data to support improved outcome by screening and some evidence to suggest that there is no beneficial effect.12, 15, 31 Because of the tremendous impact

Overview

Once lung cancer is diagnosed, it next becomes important to determine the extent of disease. Distant metastases are found in nearly 40% of patients with newly diagnosed lung cancer.5 The presence of local extension and invasion, as well as the presence of metastatic disease, has important treatment implications for patients with lung cancer. Careful attention, therefore, should be paid to the recommended staging processes outlined subsequently. Obviously, some, or even all, of the recommended

CONCLUSION

Lung cancer can present in a myriad of ways and the goal of prompt diagnosis and staging requires the clinician to be able to knowledgeably choose from a variety of tools available for such purpose. Review of some of these tools and general strategies with regard to staging have been provided. Many new technologies are becoming available and much evaluation remains to be done before their proper roles become well defined. Little has changed with regard to staging of SCLC in recent years. The

References (65)

  • R.R. Khajotia et al.

    Induced sputum and cytological diagnosis of lung cancer

    Lancet

    (1991)
  • D. Kondo et al.

    Endoscopic ultrasound examination for mediastinal lymph node metastases of lung cancer

    Chest

    (1990)
  • S.S. Leong et al.

    The 1997 international staging system for non-small cell lung cancer: Have all the issues been addressed?

    Chest

    (1999)
  • N. Martini et al.

    Occult carcinomas of the lung

    Ann Thorac Surg

    (1980)
  • C.F. Mountain

    Revisions in the international system for staging lung cancer

    Chest

    (1997)
  • E.F. Patz et al.

    Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma

    Chest

    (1995)
  • U.B. Prakash et al.

    Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: Analysis of 414 cases

    Mayo Clin Proc

    (1985)
  • G. Roviaro et al.

    Videothoracoscopic staging and treatment of lung cancer

    Ann Thorac Surg

    (1995)
  • A.M. Salazar et al.

    The role of transthoracic needle biopsy for the diagnosis and staging of lung cancer

    Clin Chest Med

    (1993)
  • C.A. Saunders et al.

    Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer

    Ann Thorac Surg

    (1999)
  • G.A. Silvestri et al.

    Endoscopic ultrasound with fine-needle aspiration in the diagnosis and staging of lung cancer

    Ann Thorac Surg

    (1996)
  • J.M. Wallace et al.

    Flexible fiberoptic bronchoscopy and percutaneous needle lung aspiration for evaluating the solitary pulmonary nodule

    Chest

    (1982)
  • A. Alavi et al.

    Is there a role for FDG PET imaging in the management of patients with sarcoidosis?

    J Nucl Med

    (1994)
  • American Thoracic Society/European Respiratory Society

    Pretreatment evaluation of non-small cell lung cancer

    Am J Respir Crit Care Med

    (1997)
  • C.C. Boring et al.

    Cancer statistics— 1992

    CA Cancer J Clin

    (1992)
  • C. Boutin et al.

    Thoracoscopy in malignant pleural effusions

    Am Rev Respir Dis

    (1981)
  • Canadian Lung Oncology Group

    Investigation for mediastinal disease in patients with apparently operable lung cancer

    Ann Thorac Surg

    (1995)
  • R.E. Coleman

    PET in lung cancer

    J Nucl Med

    (1999)
  • D.M. Eddy

    Screening for lung cancer

    Ann Intern Med

    (1989)
  • A.M. Fein et al.

    The solitary pulmonary nodule: A systemic approach

  • B.J. Flehinger et al.

    Current status of screening for lung cancer

    Current Perspectives in Thoracic Oncology

    (1994)
  • A. Fritscher-Ravens et al.

    Diagnostic value of endoscopic ultrasonography-guided fine-needle aspiration cytology of mediastinal masses in patients with intrapulmonary lesions and nondiagnostic bronchoscopy

    Respiration

    (1999)
  • Cited by (0)

    Address reprint requests to Gerard Silvestri, MD, 96 Jonathan Lucas Street, Suite 812, Charleston, SC 29425, e-mail: [email protected]

    *

    Division of Pulmonary and Critical Care Medicine, Allergy, and Clinical Immunology, Medical University of South Carolina, Charleston, South Carolina

    View full text